HSND80

HSND80 (Compound 1) is an orally active inhibitor of MNK/p70S6K, with Kd values of 44 nM against MNK1 and 4 nM against MNK2. HSND80 has a longer target residence time of 45 mins and 58 mins against MNK1 and MNK2 respectively. HSND80 can suppress non-small cell lung cancer (NSCLC) both in vitro and in vivo, and suppress Triple-Negative Breast Cancer (TNBC) in vitro[1].

Product Specifications

UNSPSC

12352005

Target

MNK; Ribosomal S6 Kinase (RSK)

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)C3=CN=CC(C#CC4=CN=C5C=CC(N6C[C@H](C)O[C@H](C)C6)=NN54)=C3

Molecular Formula

C33H35F3N8O2

Molecular Weight

632.68

References & Citations

[1]Riddhi Chaudhuri, et al. Morpholino nicotinamide analogs of ponatinib, dual MNK, p70S6K inhibitors, display efficacy against lung and breast cancers. Bioorganic Chemistry. 26 February 2025, 108298.